Pharvaris NV
PHVS21.780USD
+0.820+3.91%
終値 10/15, 16:00（ET）15分遅れの株価
1.19B時価総額
損失額直近12ヶ月PER
詳細情報 Pharvaris NV 企業名
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Pharvaris NVの企業情報
企業コードPHVS
会社名Pharvaris NV
上場日Feb 05, 2021
最高経営責任者「CEO」Mr. Berndt Modig, CPA
従業員数- -
証券種類Ordinary Share
決算期末Feb 05
本社所在地Emmy Noetherweg 2
都市LEIDEN
証券取引所NASDAQ Global Select Consolidated
国Netherlands
郵便番号2333 BK
電話番号31712036410
ウェブサイトhttps://pharvaris.com/
企業コードPHVS
上場日Feb 05, 2021
最高経営責任者「CEO」Mr. Berndt Modig, CPA
Pharvaris NVの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
他の
60.49%
株主統計
株主統計
比率
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
他の
60.49%
種類
株主統計
比率
Private Equity
25.72%
Investment Advisor
16.09%
Hedge Fund
14.25%
Venture Capital
13.60%
Investment Advisor/Hedge Fund
6.29%
Individual Investor
5.32%
Research Firm
0.08%
Bank and Trust
0.04%
Pension Fund
0.03%
他の
18.58%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
115
48.75M
76.10%
-1.83M
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
General Atlantic LLC
7.53M
11.76%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.42M
8.47%
+27.02K
+0.50%
Jun 30, 2025
Foresite Capital Management, LLC
4.41M
6.89%
--
--
Jun 30, 2025
VenBio Partners LLC
4.29M
6.7%
--
--
Jun 30, 2025
Viking Global Investors LP
3.65M
5.7%
--
--
Jun 30, 2025
EQT Life Sciences
3.56M
5.55%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
5.16%
--
--
Jun 30, 2025
VR Adviser, LLC
2.05M
3.2%
-1.07M
-34.22%
Jun 30, 2025
Deerfield Management Company, L.P.
2.02M
3.15%
--
--
Jun 30, 2025
Commodore Capital LP
1.91M
2.98%
--
--
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Mon, Oct 6
更新時刻: Mon, Oct 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ALPS Medical Breakthroughs ETF
0.69%
iShares MSCI Netherlands ETF
0.21%
iShares MSCI Europe Small-Cap ETF
0.03%
SPDR S&P International Small Cap ETF
0.03%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
iShares MSCI EAFE Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0%
Avantis International Small Cap Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率0.98%
ALPS Medical Breakthroughs ETF
比率0.69%
iShares MSCI Netherlands ETF
比率0.21%
iShares MSCI Europe Small-Cap ETF
比率0.03%
SPDR S&P International Small Cap ETF
比率0.03%
Xtrackers MSCI Eurozone Hedged Eqty ETF
比率0.01%
iShares MSCI EAFE Small-Cap ETF
比率0.01%
Fidelity Nasdaq Composite Index ETF
比率0%
Avantis International Small Cap Equity ETF
比率0%
First Trust IPOX Europe Equity Opportunities ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
